THNR ETF (Amplify Weight Loss Drug & Treatment ETF) is managed by Amplify ETFs with $4.2M in net assets. THNR expense ratio is 0.59%, holding 22 positions across sectors including Health Care, Unknown, Financials. Inception date: 2024-05-21.

THNR performance shows a YTD return of 3.04%. The 1-year return is 13.13%. THNR dividend yield stands at 1.59%, paid annually.

THNR top holdings include Eli Lilly & Co (13.0%), Novo Nordisk A/S ADR (11.2%), Amgen Inc. (7.4%), Regeneron Pharmaceuticals, Inc. (6.6%), Chugai Pharmaceutical Co. Ltd. Com Stk (6.5%). View all THNR holdings, sector breakdown, or dividend history.

THNR can be compared against other funds using the overlap calculator or side-by-side comparison tool. THNR alternatives are available via the screener, along with tax-loss harvesting opportunities.